Summary
- NVO, which has so far dominated the diabetes market, is expected to face tough times as competition is growing fierce and strong and will unfavorably impact NVO share.
- Launch of four new basal insulin products over the next 2 years will constrain the growth prospects for NVO’s basal insulin product Levemir.
- NVO’s fastest growing product Victoza will eventually meet strong competitors that may offer considerable benefits over Victoza.
- Insulin market growth will slow down for three reasons.
